03361naa a22005177i 4500001002500000003000600025005001700031006001900048007001500067008004100082024003600123035003200159040002200191041000800213100003400221245018700255264005700442300003500499336002600534337002600560338003600586500003800622500004800660506011200708520105900820540012801879546001602007588012802023590005802151650002302209650002702232650002202259653003802281653003202319653001902351655002102370700002402391700003502415700003002450700003102480773007902511856009302590884013902683942000602822999001502828UMUN-OA-20261005-MLS-052local20261005174905.0m o d cr||||||||||||261005s2020 xx o u000 0 eng d7 a10.1186/s12931-020-01570-22doi a(local)EuropePMC:PMC7677848 alocalbengclocal0 aeng0 aGrégoire Ruffenacheauthor.10aPulmonary hypertension secondary to pulmonary fibrosis: clinical data, histopathology and molecular insights. /cGrégoire Ruffenach; Jason Hong; Mylène Vaillancourt [and others]. 1a[Place of publication not identified] :bBMC,c2020. a1 online resource (1 article). atextbtxt2rdacontent acomputerbc2rdamedia aonline resourcebcr2rdacarrier aPublication type: Review article. aLinked open-access copy: published version.0 aOpen access; no subscription required for the linked open-access version.fUnrestricted online access2star3 aPulmonary hypertension (PH) developing secondarily in pulmonary fibrosis (PF) patients (PF-PH) is a frequent co-morbidity. The high prevalence of PH in PF patients is very concerning since the presence of PH is a strong predictor of mortality in PF patients. Until recently, PH was thought to arise solely from fibrotic destruction of the lung parenchyma, leading to hypoxic vasoconstriction and loss of vascular bed density. Thus, potential cellular and molecular dysregulation of vascular remodeling as a driver of PF-PH has been under-investigated. The recent demonstrations that there is no correlation between the severity of the fibrosis and development of PH, along with the finding that significant vascular histological and molecular differences exist between patients with and without PH have shifted the etiological paradigm of PF-PH. This review aims to provide a comprehensive translational overview of PH in PF patients from clinical diagnosis and outcome to the latest understanding of the histology and molecular pathophysiology of PF-PH. aCreative Commons Attribution. See the linked licence for the applicable terms.uhttp://creativecommons.org/licenses/by/4.0/ aIn English.0 aDescription generated from Europe PMC bibliographic metadata retrieved on 5 October 2026; full text linked from the source. aCourse allocation: B. Sc. Medical Laboratory Science. 4aPulmonary fibrosis 4aPulmonary hypertension 4aVascular diseases aB. Sc. Medical Laboratory Science aUMUN open access collection ahistopathology 4aReview articles.0 aJason Hongeauthor.0 aMylène Vaillancourteauthor.0 aLejla Medzikoviceauthor.0 aMansoureh Eghbalieauthor.0 tRespiratory researchgVol. 21, no. 1, (2020), pages/article 303x1465-992140uhttps://europepmc.org/articles/PMC7677848yRead open-access publicationzOpen access.70 aCourse selection and automated MARC21 enrichment from Europe PMC metadata.g20261005khttps://europepmc.org/articles/PMC7677848qlocal n0 c1194d1194